Business Responsibility and Sustainability Report for FY 2025-26

SUPRIYA LIFESCIENCE LTD. " Creati11g true values that bind global l,ealtl, September 1, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex Mumbai- 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543434 NSE Symbol: SUPRIYA Dear Sir (s), Sub: Notice of the 18th Annual General Meeting, Annual Report FY 2025-26 and the Business Responsibility and Sustainability Report Further to our Letter dated August 26, 2026, convening that the 18th Annual General Meeting ("AGM") of the Members of the Company is scheduled to be held on Thursday, September 24, 2026, at 03:00 p.m. (IST) through Video Conferencing/ Other Audio Visual Means in accordance with relevant circulars issued by the Ministry of Corporate Affairs and SEBI. Pursuant to Regulation 34(1) and Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company for the financial year 2025-26 including the Business Responsibility and Sustainability Report, along with the Notice of AGM, which are being sent through electronic mode to the Members of the Company, whose email IDs are registered with Depositories/ Company/ Registrar and Share Transfer Agent. The Annual Report along with the Notice of the AGM for the Financial Year 2025-26 is also available on the website of the Company at www.supriyalifescience.com under “Investor Section”. The Notice of AGM of the Company inter alia indicates the process and manner of remote e-voting/ e-voting at the AGM and instructions for participating at the AGM through VC/OAVM. Kindly take the said information on your records. Thanking you, Yours faithfully, For Supriya Lifescience Limited Prachi Sathe Company Secretary & Compliance Officer Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India. Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience .com Website: www.supriyalifescience.com Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India. Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com GOVT. RECOGNISED EXPORT HOUSE Annual Report 2025-26 CO FS Statutory Reports SR Business Responsibility and Sustainability Report SECTION A- GENERAL DISCLOSURES I. Details of the listed entity 1. Corporate Identity Number (CIN) of the listed entity L51900MH2008PLC180452 2. Name of the listed entity Supriya Lifescience Limited 3. Year of incorporation 26/03/2008 4. Registered office address 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400063, Maharashtra, India. 5. Corporate address 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400063, Maharashtra, India. 6. E-mail cs@supriyalifescience.com 7. Telephone 022-40332727 8. Website www.supriyalifescience.com 9. Financial year for which reporting is being done April 1, 2025, to March 31, 2026 10. Name of the Stock Exchange(s) where shares are listed 1. BSE Limited (“BSE”) 2. The National Stock Exchange of India Limited (“NSE”) 11. Paid-up Capital ₹ 160.97 million 12. Name and contact details (telephone, email address) Dr. Saloni Satish Wagh of the person who may be contacted in case of any Managing Director queries on the BRSR report. Tel. No.: 022 4033 2727 Email id: supriya@supriyalifescience.com 13. Reporting boundary - Are the disclosures under this Standalone Basis report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together). 14. Name of assurance provider NA 15. Type of assurance obtained Not applicable II. Products/services 16. Details of business activities (accounting for 90% of the turnover): S. % of Turnover of Description of Main Activity Description of Business Activity No. the entity 1 Manufacturing of Active Pharmaceutical Manufacturing of Active Pharmaceutical 98.17 Ingredients Ingredients 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): S. % of total Turnover Product/Service NIC Code No. contributed 1 Manufacturing & Sale of Active Pharmaceutical Ingredients 21001 98.17 Supriya Lifescience Ltd. SUPRIYA LIFESCIENCE LTD. III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of Plants Number of Offices Total National 3 1 4 International 0 0 0 19. Markets served by the entity: a. Number of locations Location Number National (No. of States) 28 International (No. of Countries) 128 b. What is the contribution of exports as a percentage of the total turnover of the entity? c. A brief on types of customers Our diversified customer base comprises innovator companies, generic formulation manufacturers, and traders across a wide range of geographies. IV. Employees 20. Details as at the end of Financial Year a. Employees and workers (including differently abled): Male Female No Particulars Total(A) No(B) %(B/A) No(C) %(C/A) Employees 1 Permanent (D) 607 546 89.95% 61 10.05% 2 Other than Permanent (E) 703 697 99.15% 6 0.85% 3 Total employees (D + E) 1310 1243 94.89% 67 5.11% Workers 1 Permanent (F) 0 0 NA 0 NA 2 Other than Permanent (G) 0 0 NA 0 NA 3 Total Workers (F + G) 0 0 NA 0 NA b. Differently abled Employees and workers: Male Female No Particulars Total(A) No(B) %(B/A) No(C) %(C/A) Differently Abled Employees 1 Permanent (D) 0 0 NA 0 NA 2 Other than Permanent (E) 0 0 NA 0 NA 3 Total differently abled employees (D + E) 0 0 NA 0 NA Differently Abled Workers 1 Permanent (F) 0 0 NA 0 NA 2 Other than Permanent (G) 0 0 NA 0 NA 3 Total Workers (F + G) 0 0 NA 0 NA 21. Participation/Inclusion/Representation of women No. and percentage Total(A) of Females No(B) %(B/A) Board of Directors 10 4 40.00% Key Management Personnel 2 1 50.00% Annual Report 2025-26 CO FS Statutory Reports SR 22. Turnover rate for permanent employees and workers. (Disclose trends for the past 3 years) FY 2023-2024 FY 2025-2026 FY 2024-2025 (Turnover rate in the year (Turnover rate in current FY) (Turnover rate in previous FY) prior to the previous FY) Male Female Total Male Female Total Male Female Total Permanent Employees 13.78% 9.60% 13.37% 19.1% 14.9% 18.67% 23.99% 14.46% 21.00% Permanent Workers - - - - - - - - - Holding, Subsidiary and Associate Companies (including joint ventures) 23. (a) Names of holding / subsidiary / associate companies / joint ventures. Name of the holding / Does the entity indicated at column Indicate whether % of shares S. subsidiary / associate A, participate in the Business holding/ subsidiary/ held by listed No. companies / joint Responsibility initiatives of the listed associate/ joint venture entity ventures (A) entity? (Yes/No) 1 Nil Nil Nil Nil VI. CSR Details 24. Provide the following CSR details i) Whether CSR is applicable as per section 135 of Companies Act, 2013 - Yes ii) Turnover (in Rs.) – 8278.75 million iii) Net worth (in Rs.) – 11977.33 million VII. Transparency and Disclosures Compliances 25. C omplaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct: -FY 2025-2026 -FY 2024-2025 Number of Number of Stakeholder Grievance Redressal Mechanism in Place Number of complaints Number of complaints group from (Yes/No) (If Yes, then provide web-link for complaints pending complaints pending whom complaint Remarks Remarks grievance redress policy) filed during resolution filed during resolution is received the year at close of the year at close of the year the year Communities Yes, weblink for policy can be accessed 0 0 NA 0 0 NA at: https://supriyalifescience. com/ assets/pdfs/ corporategovernance/ policies/Grievance%20 policy.pdf Investors Yes, [Showing first 8,000 characters — download PDF for full document]